Moderna Shares Fall - Search News

COVID, Moderna

Moderna sales get lift from early nod for newest COVID shot

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s COVID boosters.

FiercePharma · 2d

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,

Wall Street Journal · 2d

Moderna Stock Jumps on Better-Than-Expected Covid-19 Vaccine Sales

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.

Reuters on MSN · 2d

Moderna reports surprise profit on higher-than-expected COVID vaccine sales

Moderna reported a surprise third-quarter profit on Thursday, driven by cost-cuts and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.

3don MSN

Moderna Q3 2024 Preview: Revenue to fall due to continued COVID market share decline

Moderna (NASDAQ:MRNA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. Analysts ...

Buy, Sell, Or Hold MRNA Stock?

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

10d

Moderna Inc. stock underperforms Wednesday when compared to competitors

Shares of Moderna Inc. MRNA shed 0.91% to $54.72 Wednesday, on what proved to be an all-around poor trading session for the ...

Seeking Alpha on MSN2d

Moderna swings to profits as new COVID shot powers Q3 beat

Shares of Moderna (NASDAQ:MRNA) traded ~7% higher in the premarket on Thursday after the company swung back to profits on ...

Moderna price target lowered to $111 from $125 at Barclays

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Moderna EPS Beats Estimates, Sales Rise

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

The Boston Globe4d

Moderna’s Bancel steps down as sales chief, keeps CEO role

Moderna shares fell more than 1.5 percent and had lost 46 percent this year through Monday’s close. Bancel had led sales and marketing after the company announced in December that Arpa Garay was ...

12d

Moderna price target lowered to $60 from $105 at Evercore ISI

Evercore ISI analyst Cory Kasimov lowered the firm’s price target on Moderna (MRNA) to $60 from $105 and keeps an In Line rating on the ...

10d

Should I buy GSK shares at £14 after the Q3 trading update?

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results